News & Views - Page 51 of 54 - Telix Pharmaceuticals Limited

Telix and University of Melbourne Establish Cancer Translational Research Partnership

Telix is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of Melbourne.

Telix Pharmaceuticals files $50M Underwritten Initial Public Offering

Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public Offering.

Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology

Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology (VisAcT).

Kevin McCann and Mark Nelson Appointed to the Board of Directors of Telix

Telix is pleased to announce today that Mr. Kevin McCann AM and Dr. Mark Nelson have been appointed to the Board of Telix Pharmaceuticals Limited as Non-Executive Directors.

Telix and Cyclotek Conclude Radiopharmaceutical Manufacturing Agreement for Australia and New Zealand

Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd (Cyclotek).

Abzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

Telix is pleased to announce a licence agreement collaboration with Abzena plc (Abzena) for its prostate-specific membrane antigen antibodies (PSMA).

Telix Pharmaceuticals and Atlab Pharma Conclude Therapeutic Product Development Agreement for Prostate Cancer

Telix is pleased to announce the completion of a product collaboration and purchase option agreement with Atlab Pharma SAS (Atlab).

Telix Pharmaceuticals Acquires Glioblastoma Program from Therapeia

Telix is pleased to announce a product development partnership with Therapeia GmbH & Co KG (“Therapeia”).

Wilex Signs Antibody License Agreement With Telix Pharmaceuticals Limited

Telix is delighted to have established this licensing agreement with Wilex for an important product with the potential to significantly impact cancer care.